2024-05-09 17:13:21 ET
More on Gilead Sciences, Arcellx
- Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript
- Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation
- Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?
- Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus
- Gilead Sciences Non-GAAP EPS of -$1.32 beats by $0.20, revenue of $6.69B beats by $350M
Read the full article on Seeking Alpha
For further details see:
Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset